Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 33

1.

Soluble Expression and Characterization of Biologically Active Bacillus anthracis Protective Antigen in Escherichia coli.

Suryanarayana N, Vanlalhmuaka, Mankere B, Verma M, Thavachelvam K, Tuteja U.

Mol Biol Int. 2016;2016:4732791. doi: 10.1155/2016/4732791. Epub 2016 Feb 7.

2.

Structural hot spots for the solubility of globular proteins.

Ganesan A, Siekierska A, Beerten J, Brams M, Van Durme J, De Baets G, Van der Kant R, Gallardo R, Ramakers M, Langenberg T, Wilkinson H, De Smet F, Ulens C, Rousseau F, Schymkowitz J.

Nat Commun. 2016 Feb 24;7:10816. doi: 10.1038/ncomms10816.

3.

Whole genome protein microarrays for serum profiling of immunodominant antigens of Bacillus anthracis.

Kempsell KE, Kidd SP, Lewandowski K, Elmore MJ, Charlton S, Yeates A, Cuthbertson H, Hallis B, Altmann DM, Rogers M, Wattiau P, Ingram RJ, Brooks T, Vipond R.

Front Microbiol. 2015 Aug 13;6:747. doi: 10.3389/fmicb.2015.00747. eCollection 2015.

4.

Natural cutaneous anthrax infection, but not vaccination, induces a CD4(+) T cell response involving diverse cytokines.

Ingram RJ, Ascough S, Reynolds CJ, Metan G, Doganay M, Baillie L, Williamson DE, Robinson JH, Maillere B, Boyton RJ, Altmann DM.

Cell Biosci. 2015 Apr 26;5:20. doi: 10.1186/s13578-015-0011-4. eCollection 2015.

5.

Anthrax lethal factor as an immune target in humans and transgenic mice and the impact of HLA polymorphism on CD4+ T cell immunity.

Ascough S, Ingram RJ, Chu KK, Reynolds CJ, Musson JA, Doganay M, Metan G, Ozkul Y, Baillie L, Sriskandan S, Moore SJ, Gallagher TB, Dyson H, Williamson ED, Robinson JH, Maillere B, Boyton RJ, Altmann DM.

PLoS Pathog. 2014 May 1;10(5):e1004085. doi: 10.1371/journal.ppat.1004085. eCollection 2014 May.

6.

In vitro and in vivo activities of recombinant anthrax protective antigen co-expressed with thioredoxin in Escherichia coli.

Ma Y, Yu YZ, Zhu YF, Xu Q, Sun ZW.

Hum Vaccin Immunother. 2013 Nov;9(11):2371-7. Epub 2013 Jul 23.

7.

A single-dose PLGA encapsulated protective antigen domain 4 nanoformulation protects mice against Bacillus anthracis spore challenge.

Manish M, Rahi A, Kaur M, Bhatnagar R, Singh S.

PLoS One. 2013 Apr 29;8(4):e61885. doi: 10.1371/journal.pone.0061885. Print 2013.

8.

Anthrax lethal toxin and the induction of CD4 T cell immunity.

Ascough S, Ingram RJ, Altmann DM.

Toxins (Basel). 2012 Oct;4(10):878-99. doi: 10.3390/toxins4100878. Epub 2012 Oct 19. Review.

9.

Comparison of the structural stability and dynamic properties of recombinant anthrax protective antigen and its 2-fluorohistidine-labeled analogue.

Hu L, Joshi SB, Andra KK, Thakkar SV, Volkin DB, Bann JG, Middaugh CR.

J Pharm Sci. 2012 Nov;101(11):4118-28. doi: 10.1002/jps.23294. Epub 2012 Aug 21.

10.

Bacillus anthracis edema factor substrate specificity: evidence for new modes of action.

Göttle M, Dove S, Seifert R.

Toxins (Basel). 2012 Jul;4(7):505-35. doi: 10.3390/toxins4070505. Epub 2012 Jul 6. Review.

11.
12.

Principles of antidote pharmacology: an update on prophylaxis, post-exposure treatment recommendations and research initiatives for biological agents.

Ramasamy S, Liu CQ, Tran H, Gubala A, Gauci P, McAllister J, Vo T.

Br J Pharmacol. 2010 Oct;161(4):721-48. doi: 10.1111/j.1476-5381.2010.00939.x. Review.

13.

Substrate-mediated stabilization of a tetrameric drug target reveals Achilles heel in anthrax.

Voss JE, Scally SW, Taylor NL, Atkinson SC, Griffin MD, Hutton CA, Parker MW, Alderton MR, Gerrard JA, Dobson RC, Dogovski C, Perugini MA.

J Biol Chem. 2010 Feb 19;285(8):5188-95. doi: 10.1074/jbc.M109.038166. Epub 2009 Nov 30.

14.

Technical transformation of biodefense vaccines.

Lu S, Wang S.

Vaccine. 2009 Nov 5;27 Suppl 4:D8-D15. doi: 10.1016/j.vaccine.2009.08.055. Review.

15.

Anthrax vaccination strategies.

Cybulski RJ Jr, Sanz P, O'Brien AD.

Mol Aspects Med. 2009 Dec;30(6):490-502. doi: 10.1016/j.mam.2009.08.006. Epub 2009 Sep 1. Review.

16.

Neutralizing monoclonal antibodies directed against defined linear epitopes on domain 4 of anthrax protective antigen.

Kelly-Cirino CD, Mantis NJ.

Infect Immun. 2009 Nov;77(11):4859-67. doi: 10.1128/IAI.00117-09. Epub 2009 Aug 24.

17.

Investigation of new dominant-negative inhibitors of anthrax protective antigen mutants for use in therapy and vaccination.

Cao S, Guo A, Liu Z, Tan Y, Wu G, Zhang C, Zhao Y, Chen H.

Infect Immun. 2009 Oct;77(10):4679-87. doi: 10.1128/IAI.00264-09. Epub 2009 Jul 20.

18.

Mucosal immunization with attenuated Salmonella enterica serovar Typhi expressing protective antigen of anthrax toxin (PA83) primes monkeys for accelerated serum antibody responses to parenteral PA83 vaccine.

Galen JE, Chinchilla M, Pasetti MF, Wang JY, Zhao L, Arciniega-Martinez I, Silverman DJ, Levine MM.

J Infect Dis. 2009 Feb 1;199(3):326-35. doi: 10.1086/596066.

19.

Non-canonical effects of anthrax toxins on haematopoiesis: implications for vaccine development.

Liu K, Wong EW, Schutzer SE, Connell ND, Upadhyay A, Bryan M, Rameshwar P.

J Cell Mol Med. 2009 Aug;13(8B):1907-19. doi: 10.1111/j.1582-4934.2008.00477.x. Epub 2008 Dec 10.

20.

In vivo efficacy of a phosphodiester TLR-9 aptamer and its beneficial effect in a pulmonary anthrax infection model.

Wu CC, Sabet M, Hayashi T, Tawatao R, Fierer J, Carson DA, Guiney DG, Corr M.

Cell Immunol. 2008 Feb;251(2):78-85. doi: 10.1016/j.cellimm.2008.04.001. Epub 2008 May 20.

Supplemental Content

Support Center